HTLV-1 associated T cell lymphoma in South East Asia: Case report and family study

T L Wang, T C Liu, L Chan, Y K Kueh, S Y Wong

Abstract
Geographic clustering of human T cell lymphoma/leukaemia virus type 1 (HTLV-1) infection is well recognised, particularly in south western Japan, parts of West and Central Africa, the south eastern United States and the Caribbean islands.1 Sporadic cases have been reported in many other parts of the world. The first case of HTLV-1 associated leukaemia/lymphoma (ATLL) in South East Asia is reported. Contact tracing showed a high incidence of carriers among the relatives.

Case report
A 52 year old Chinese woman was referred for evaluation of an abdominal mass and cervical lymphadenopathy. A cervical lymph node was subsequently biopsied. Sections showed the nodal architecture to be completely effaced by neoplastic lymphoid cells which exhibited a high mitotic rate and displayed bizarre shapes with pronounced nuclear variation and multilobation (fig A). Immunophenotyping using a panel of monoclonal antibodies applied to cryostat sections of fresh lymph node tissue showed surface expression of CD2, CD8, HLA-DR and CD25 with weak positivity for CD4 and CD7 in the lymphoid cells (figs B–D). The features were compatible with a high grade pleomorphic medium and large cell type, T-cell non-Hodgkin’s lymphoma.2

Staging of her disease showed marrow infiltration by similar pleomorphic lymphoid cells and pronounced para-aortic lymphadenopathy. She was treated with combination chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone), but she died from progressive disease two months after diagnosis.

In view of the histological findings we tested her serum for the presence of antibodies to HTLV-1. An enzyme linked immunosorbent assay (ELISA) showed reactivity to HTLV-1 viral proteins and Western blot analysis (Diagnostic Biotechnology, Singapore) showed reactivity to both gag and env HTLV-1 proteins. She was seronegative for antibody to human immunodeficiency virus.

A high incidence of HTLV-1 infections among relatives of patients with HTLV-1 associated leukaemia/lymphoma can be expected.3 We tested the sera of nine of her relatives. Four (44%) of them had HTLV-1 infections by both enzyme linked immunosorbent assay and Western blot analysis (fig E).
None of them had a history suggestive of tropical spastic paraparesis, the other known syndrome associated with HTLV-1 infection. Our patient was a second generation immigrant from south China. She had never travelled to HTLV-1 endemic areas, but had received a blood transfusion for post-partum haemorrhage during delivery of her first child.

Comment
HTLV-1 infections have not been widely documented in east Asia outside of Japan and Taiwan. The seroepidemiological pattern of this infection in South East Asia has not been well studied. A recent serological survey of 9689 healthy blood donors and pregnant women in Singapore showed an incidence of 0.03% (unpublished data). This is close to the 0.025% seroprevalence documented in blood donors of the United States.

The fact that both vertical and horizontal transmission of this infection can readily occur is well illustrated by this case. This ease of transmission is of concern, especially when pockets of HTLV-1 infection have been documented in unusual areas. At the least, seroepidemiological trends must be monitored to ensure that the problem does not take on greater proportions.

The low seroprevalence of HTLV-1 in non-endemic areas is likely to preclude cost-effective screening of blood donors. Patients with mature T-cell lymphoid malignancies, however, should be screened for infection. Contact tracing after identification of the index case is likely to be fruitful. The detection of infected patients, together with counselling on the modes of transmission, may help to prevent further transmission and protect national blood resources.

We thank Dr T P Yin of the Specialist Centre in Penang for his cooperation. This work was supported in part by the National University of Singapore Biological Sciences Research Project RP 890383.


Treatment of acute myeloid leukaemia in a renal allograft recipient: Implications of cyclosporin immunosuppressive treatment

R J G Guthbert, N H Russell, P A E Jones, A G Morgan

Abstract
The clinical effects of cyclosporin were evaluated during cytotoxic treatment in a 61 year old man with acute myeloid leukaemia. He had required a renal transplant 18 months before presenting with acute myeloid leukaemia (FAB subtype M4). He had received cyclosporin 3.5–4.0 mg/kg daily to maintain a plasma cyclosporin concentration of 75–150 ng/ml. Cyclosporin was continued during induction chemotherapy with daunorubicin, cytarabine, and 6-thioguanine (DAT). He had fever and oropharyngeal candidiasis that was unresponsive to anti-bacterial drugs but responsive to systemic amphotericin. Bone marrow examination 14 days after chemotherapy showed complete haematological remission. Subsequently he tolerated consolidation treatment with DAT with no serious complications. Unfortunately he developed fatal septicaemia following a second consolidation with mitozantrone and cytarabine.

Inhibition of P-glycoprotein activity by cyclosporin may not significantly increase the toxicity of aggressive chemotherapeutic regimens, and as benefit may be achieved by this approach further clinical evaluation is justified.

In the management of malignant disease resistance to cytotoxic drugs often makes treatment unsuccessful. Interest has developed in studying the possible benefits of inhibiting the activity of P-glycoprotein to circumvent cytotoxic drug resistance. P-glycoprotein is a 170 kilodalton transmembrane glycoprotein which acts as an energy dependent pump, causing active efflux of structurally hetero-
HTLV-1 associated T cell lymphoma in South East Asia: case report and family study.

T L Wang, T C Liu, L Chan, Y K Kueh and S Y Wong

doi: 10.1136/jcp.44.8.692

Updated information and services can be found at:
http://jcp.bmj.com/content/44/8/692

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/